General Health

Digital Stethoscope HeartScreen Wins First Place, $70,000 in Chicago Booth’s Global New Venture Challenge

Friday, June 11, 2021 - 7:51pm

The teams hail from Booths three campuses Chicago, London and Hong Kong each of which held a semifinals event.

Key Points: 
  • The teams hail from Booths three campuses Chicago, London and Hong Kong each of which held a semifinals event.
  • The regional winners presented their business plans to a panel of judges and investors in Thursdays global finals.
  • The 2021 GNVC winners are:
    First place ($70,000): HeartScreen // HeartScreen is a subscription-based telemedicine platform that transforms a smartphone into a digital stethoscope that acquires heart sounds in real-time.
  • The GNVC is one of five tracks of the New Venture Challenge, which this year marks its 25th anniversary.

Inspira Health Appoints Anneliese McMenamin, SPHR, SHRM-SCP as Chief Human Resources Officer

Friday, June 11, 2021 - 7:07pm

Inspira Health today announced the appointment of Anneliese McMenamin, SPHR, SHRM-SCP, to Chief Human Resources Officer, effective August 9.

Key Points: 
  • Inspira Health today announced the appointment of Anneliese McMenamin, SPHR, SHRM-SCP, to Chief Human Resources Officer, effective August 9.
  • View the full release here: https://www.businesswire.com/news/home/20210611005444/en/
    Anneliese McMenamin, SPHR, SHRM-SCP, Inspira Health's Chief Human Resources Officer (Photo: Business Wire)
    McMenamin has more than three decades of experience in human resources, including 28 years in the health care industry, most recently serving as Chief Human Resources Officer and Vice President of Human Resources for Saint Barnabas Medical Center, part of RWJBarnabas Health, since 2019.
  • As Chief Human Resources Officer, McMenamin will support Inspiras growth strategy under the leadership of Amy Mansue, President & CEO of Inspira Health.
  • She is a member of the Society for Human Resources Management and Tri-State Society for Human Resources Management.

US Post-Acute Care (PAC) Market Report 2021 - ResearchAndMarkets.com

Friday, June 11, 2021 - 5:50pm

The "The US Post-Acute Care (PAC) Market: Size & Forecasts with Impact Analysis of COVID-19 (2021-2025 Edition)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The US Post-Acute Care (PAC) Market: Size & Forecasts with Impact Analysis of COVID-19 (2021-2025 Edition)" report has been added to ResearchAndMarkets.com's offering.
  • "The US Post-Acute Care (PAC) Market: Size & Forecasts with Impact Analysis of COVID-19 (2021-2025 Edition)" provides an in-depth analysis of the post-acute care market in the US including detailed description of market sizing and growth.
  • The report provides an analysis of the US post-acute care market by value, by spending, by number of providers and includes detailed segment analysis as well.
  • The COVID-19 pandemic acted as a headwind for the post-acute care market in the country in 2020.

CreakyJoints Reports that Women Endure Symptoms of Inflammatory Arthritis Despite Availability of Medications Proven Safe for Pregnant and Lactating Mothers

Friday, June 11, 2021 - 4:00pm

Data published in 2011 and 2012 demonstrated that TNFi medications (biologics) were safe to use during pregnancy and lactation in women with inflammatory forms of arthritis.

Key Points: 
  • Data published in 2011 and 2012 demonstrated that TNFi medications (biologics) were safe to use during pregnancy and lactation in women with inflammatory forms of arthritis.
  • Among those who were prescribed TNFis, 18 percent of women continued these medications through pregnancy post-2012 versus only 5 percent of women who continued these medications pre-2012 (p=0.006).
  • Forty percent of women felt that no medications were safe to use in pregnancy, whereas 41 percent selected prednisone (41%), TNFi (15%), NSAIDs (11%), hydroxychloroquine (9%), and acetaminophen (2%) as safe medications.
  • Most women were white (77%), college-educated (68%), and had rheumatoid arthritis (RA) (89%), but other inflammatory arthritis diagnoses were also represented.

Global Next-Generation Sequencing Market to 2025 - Impact of COVID-19 - ResearchAndMarkets.com

Friday, June 11, 2021 - 3:43pm

The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global market for clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a compound annual growth rate (CAGR) of 31.4% for the period of 2020-2025.
  • This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing.
  • Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct to consumer testing; and noninvasive prenatal testing.

Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi Arabia

Friday, June 11, 2021 - 1:30pm

Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia.

Key Points: 
  • Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia.
  • We appreciate the collaboration of Tabuk Pharmaceuticals in this new partnership in Saudi Arabia, said Stphane Bancel, Chief Executive Officer of Moderna.
  • We welcome the opportunity to work with Tabuk Pharmaceuticals to bring the Moderna COVID-19 and potentially other Moderna mRNA products to Saudi Arabia in the future, said Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna.
  • Established in Saudi Arabia in 1994, Tabuk Pharmaceuticals is a leading regional pharmaceutical in the Middle East and North Africa (MENA).

Telix Launches “Gallium Wave” Awareness Website

Friday, June 11, 2021 - 1:04pm

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced the launch of a new website Gallium Wave ( galliumwave.com ), as part of the Company's gallium awareness campaign.

Key Points: 
  • Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced the launch of a new website Gallium Wave ( galliumwave.com ), as part of the Company's gallium awareness campaign.
  • The website illustrates how Telix, in partnership with suppliers, manufacturers and distributors, is paving a new path to increase future access to gallium-68 (68Ga) based radiopharmaceuticals.
  • We are excited to launch this educational resource to increase physician awareness of the reliability, flexibility and accessibility of 68Ga.
  • Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases.

Orthofix Announces Participation in Upcoming JMP Securities Life Sciences Conference

Friday, June 11, 2021 - 12:01pm

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 11:00 a.m.

Key Points: 
  • Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 11:00 a.m.
  • The conference will be held in a virtual format, and one-on-one meetings will be held before and immediately following the fireside chat.
  • Orthofix Medical Inc. is a global medical device company with a spine and orthopedics focus.
  • The Companys mission is to deliver innovative, quality-driven solutions while partnering with health care professionals to improve patient mobility.

ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting

Friday, June 11, 2021 - 12:15pm

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that shareholders approved all of the resolutions as proposed by the Board of Directors at yesterday's Annual General Meeting (AGM).

Key Points: 
  • ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that shareholders approved all of the resolutions as proposed by the Board of Directors at yesterday's Annual General Meeting (AGM).
  • Shareholders approved the proposed compensation of the Board of Directors and the Executive Committee, for a term of one year.
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs).
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Friday, June 11, 2021 - 12:30pm

Vice President, Clinical Development

Key Points: 
  • Vice President, Clinical Development
    Speakers: Scott Braunstein, M.D., Chief Executive Officer and Joe Hulihan, M.D., Chief Medical Officer
    All of the above public webcasts may be accessed through the Events & Presentations page of the Investors & Media section of the Marinus website, www.marinuspharma.com .
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.